Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$25.56
▲ $0.93 (+3.8%)
Market data updated: 09/24 09:56 PM
Fundamentals updated: 09/24/2026
News analyzed: 09/24/2026
Market Cap
$1.02B
Day Range
$24.58 - $25.60
52-Week Range
$18.80 - $27.66
Beta
—
Next Earnings
04.11.2026
Support
$22.79
Resistance
$27.66
PCRX is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-2.5% (1Y)
Strengths: 11/31 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
DCF Fair Value
Estimated fair value: $43.54 vs. price $25.56 (+70.4%)
Fair Value
Biggest negative driver
Operating margin stability
Operating margin is eroding over time
Quality
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 3 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 3
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
55
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
62
Quality
42
Value
57
Momentum
61
Risk
48
Sentiment
68
Fundamental
45
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Pacira BioSciences, Inc. (PCRX) has primarily focused on its stock performance following earnings reports, with notable gains of 6.9% since its last quarterly update. The company has also seen organizational changes, including board and committee leadership adjustments ahead of its 2026 Annual General Meeting. Additionally, there has been speculation about its evolving non-opioid strategy, particularly around its gene therapy candidate PCRX-201, as well as discussions on reimbursement trends for its EXPAREL product and the potential growth catalysts tied to its pipeline and valuation.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Pacira BioSciences, Inc.. News trend score: 68. Reason: 4 of the last 20 articles are positive, versus 1 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
8
🎯 Conviction (vs. Emotion)
36
Psychology
8
Fundamentals
45
Technical
61
Valuation
57
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+1%
Market Narrative
35
Fundamental Reality
36
Narrative Gap
-1
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
Market behavior suggests a mixed but predominantly *herding* dynamic, where PCRX’s underperformance relative to peers (-1.8% vs -0.6%) may signal lagging momentum rather than euphoria or panic. The narrative-reality gap (20 points) hints at overestimation of positive momentum, while FOMO (31) and euphoria (18) are muted by valuation metrics (-41% vs. DCF). The key question: Is the stock’s lag a temporary peer rotation or a structural mispricing? Overconfidence (10) remains low, but the gap suggests traders may be anchoring to recent gains despite fundamentals.
Updated: 09/09/2026, 06:36 AM
What could change this?
👥 What the crowd believes
"Pacira BioSciences (PCRX) outlook: EXPAREL reimbursement tailwinds"
"Pacira BioSciences (PCRX) Could Be 35% Undervalued On Phase 1 Gene Therapy Progress"
"PharmaCorp announces changes to its Board of Directors and committee leadership"
"Pacira (PCRX) Up 6.9% Since Last Earnings Report"
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Charles Mackay — 79/100
🔴 Weakest match
Philip Fisher — 11/100
🗣️ Why do they disagree?
The stark contrast in verdicts for PCRX reflects deep methodological divides between risk tolerance, market timing, and valuation rigor. Walter Bagehot’s high score and bullish liquidity verdict stand out as an outlier, prioritizing resilience in financial stress—a rare focus among these investors. Meanwhile, the majority cluster around mid-range scores (50–65) but split sharply: Graham and Marks see mixed potential due to valuation or market expectations, while Lynch and the efficient-market camp flag overpricing or weak evidence for active selection. At the lower end, Fisher’s near-zero score and Nelson’s overbought warning highlight divergent growth-quality criteria, with Fisher’s strict standards rejecting the stock entirely, while cycle-sensitive investors like Marks and Housel warn of late-stage risks. The debate hinges on whether PCRX’s volatility or speculative momentum (noted by Mackay) merits entry—or if its lack of clear trends (Livermore) or statistical cheapness (Graham’s Enterprising Investor) makes it a high-risk bet.
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 79
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 74
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟢 69
Risk appears reasonably priced — no obvious cycle-timing red flag
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 64
Mixed — doesn't clearly pass Graham's tests
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 56
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 52
Mixed — growth exists but the price already reflects much of it
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 48
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 47
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟡 46
Mid-cycle — no strong signal either way
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 45
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 39
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 39
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 35
Doesn't show the stability Smith's long-term case requires
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 29
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🔴 24
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 11
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Based on the last 283 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (5 bullish · 3 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
79.4%
Operating Margin
2.6%
Net Margin
1.0%
EBITDA Margin
15.2%
ROE
1.0%
ROA
0.6%
ROIC
—
EPS
$0.16
Cash
$158.54M
Total Debt
$372.19M
Current Ratio
4.54
Debt/Equity
0.54
How is Fair Value calculated? →
Current Price
$25.56
Estimated Fair Value (DCF)
$43.54
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
+70.4%
🟢 Appears cheap relative to estimated value
Year 1 Growth Rate
2.9%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 2.9% | $140.63M | $129.01M |
| 2 | 2.8% | $144.56M | $121.68M |
| 3 | 2.7% | $148.47M | $114.64M |
| 4 | 2.6% | $152.33M | $107.91M |
| 5 | 2.5% | $156.14M | $101.48M |
Base FCF (last actual year)
$136.66M
Terminal Value
$2.46B
Present Value of Terminal Value
$1.60B
Enterprise Value
$2.17B
Net Debt
$213.64M
Equity Value
$1.96B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$15.39
Tangible Book Value per Share (Tangible NAV)
$6.77
Sentiment based on basic keywords (not AI) — 4 positive, 15 neutral, 1 negative out of the last 20 articles.
Benzinga · 23.9.2026
ChartMill · 11.9.2026
Yahoo · 9.9.2026
GlobeNewswire · 9.9.2026
MT Newswires · 9.9.2026
Benzinga · 9.9.2026
Zacks · 4.9.2026
Yahoo · 4.9.2026
Zacks · 3.9.2026
Yahoo · 3.9.2026
Yahoo · 27.8.2026
GlobeNewswire · 27.8.2026
Motley Fool · 12.8.2026
Simply Wall St. · 10.8.2026
SeekingAlpha · 7.8.2026
GlobeNewswire · 7.8.2026
Simply Wall St. · 6.8.2026
GlobeNewswire · 6.8.2026
Benzinga · 6.8.2026
Zacks · 5.8.2026
Pacira BioSciences, Inc. (PCRX) currently has a StockIQ AI score of 55/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
PCRX currently scores 55/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, PCRX's estimated fair value is $43.54, which is 70.4% above the current price of $25.56. This is one valuation model among several signals in the fair-value category, not a price target.
PCRX's technical score is 61/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Estimated fair value: $43.54 vs. price $25.56 (+70.4%); Earnings per share (EPS) growth: 107.4%; Net income growth: 107.1%.
Based on the real signals StockIQ computed: Operating margin is eroding over time; Calmar: -0.12 (3y annualized return -8.0% / max drawdown 67.0%); Free cash flow growth: -23.5%.
StockIQ has no recorded dividend payment history for PCRX.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 3 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| SLONIN JONATHAN | Open Market Sale | 17.8.2026 | 3,040 | -3,040 | $23.23 |
| RIKER LAUREN | Open Market Sale | 11.6.2026 | 6,115 | -6,115 | $23.50 |
| RIKER LAUREN | Open Market Sale | 11.6.2026 | 62,284 | -6,115 | $23.50 |
| BIGAL MARCELO | Grant/Award from Employer | 10.6.2026 | 10,891 | +10,891 | — |
| Froimson Mark | Grant/Award from Employer | 10.6.2026 | 6,405 | +6,405 | — |
| YANG MICHAEL J. | Grant/Award from Employer | 10.6.2026 | 6,405 | +6,405 | — |
| Brege Laura | Grant/Award from Employer | 10.6.2026 | 10,891 | +10,891 | — |
| WIGGANS THOMAS G | Grant/Award from Employer | 10.6.2026 | 32,675 | +32,675 | — |
| Young Alethia | Grant/Award from Employer | 10.6.2026 | 10,891 | +10,891 | — |
| YANG MICHAEL J. | Grant/Award from Employer | 10.6.2026 | 10,891 | +10,891 | — |
| CHRISTIE CHRISTOPHER | Grant/Award from Employer | 10.6.2026 | 6,405 | +6,405 | — |
| Hirawat Samit | Grant/Award from Employer | 10.6.2026 | 6,405 | +6,405 | — |
| Young Alethia | Grant/Award from Employer | 10.6.2026 | 6,405 | +6,405 | — |
| Hirawat Samit | Grant/Award from Employer | 10.6.2026 | 10,891 | +10,891 | — |
| CHRISTIE CHRISTOPHER | Grant/Award from Employer | 10.6.2026 | 10,891 | +10,891 | — |
| Brege Laura | Grant/Award from Employer | 10.6.2026 | 6,405 | +6,405 | — |
| BIGAL MARCELO | Grant/Award from Employer | 10.6.2026 | 6,405 | +6,405 | — |
| Froimson Mark | Grant/Award from Employer | 10.6.2026 | 10,891 | +10,891 | — |
| WIGGANS THOMAS G | Grant/Award from Employer | 10.6.2026 | 32,675 | +32,675 | — |
| Brege Laura | Grant/Award from Employer | 10.6.2026 | 30,120 | +6,405 | — |
| Brege Laura | Grant/Award from Employer | 10.6.2026 | 10,891 | +10,891 | — |
| Froimson Mark | Grant/Award from Employer | 10.6.2026 | 26,541 | +6,405 | — |
| Froimson Mark | Grant/Award from Employer | 10.6.2026 | 10,891 | +10,891 | — |
| BIGAL MARCELO | Grant/Award from Employer | 10.6.2026 | 17,798 | +6,405 | — |
| BIGAL MARCELO | Grant/Award from Employer | 10.6.2026 | 10,891 | +10,891 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
7,561,153 shares short as of 2026-09-15 · vs. 7,328,377 on 2026-08-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
74.3% of trading volume this week was short selling, vs. 86.3% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology